Hosted on MSN2d
Novavax Stock is Slipping After the Vaccine Maker Cut its Outlook Again
On Monday, the FDA said the company could continue testing its combination COVID-19-flu and standalone flu vaccines.
Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut
NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...
Novavax price target lowered to $12 from $14 at BofA
BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...
Hosted on MSN1d
Novavax, Inc. (NASDAQ:NVAX) Q3 2024 Earnings Call Transcript
Novavax, Inc. (NASDAQ:NVAX) Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good morning and welcome to ...
AOL2d
Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals
Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales ...
Novavax: Balancing Potential and Risk Amid Strategic Shifts and Uncertain Market Outlook
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...
Novavax to Participate in Jefferies London Healthcare Conference
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
Earnings Outlook For Novavax
Analysts are estimating that Novavax will report an earnings per share (EPS) of $-0.87. Anticipation surrounds Novavax's ...
Novavax’s stock slides 7% as guidance cut offsets narrower-than-expected third-quarter loss
NovaVax Inc.’s stock NVAX tumbled 7% early Tuesday, after the company cut its full-year guidance, offsetting a narrower-than-expected third-quarter loss and better-than-expected revenue. The company ...
Novavax, Inc. (NVAX) Q3 2024 Earnings Call Transcript
Novavax, Inc. ( NASDAQ: NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET ...
Business Insider1d
Novavax’s Market Share and Pipeline Uncertainties Lead to Sell Rating
J.P. Morgan analyst Eric Joseph maintained a Sell rating on Novavax (NVAX – Research Report) yesterday and set a price target of $9.00. Eric Joseph has given his Sell rating due to a combination ...